Treating psoriasis with adalimumab

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 345-351

  Alwawi, Eihab A ^a   Mehlis, Stephanie L ^a   Gordon, Kenneth B ^a,b  

^a Division of Dermatology   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adalimumab; Psoriasis; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RETINOID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AUTOIMMUNITY; CELL ADHESION; CELL PROLIFERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DEMYELINATING DISEASE; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFECTION; INFECTION RATE; INJECTION PAIN; INJECTION SITE REACTION; KERATINOCYTE; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NAUSEA; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTOTHERAPY; POSTMARKETING SURVEILLANCE; PSORIASIS; PSORIATIC ARTHRITIS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUS CONGESTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUBERCULOSIS;

EID: 44049090388     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Abbott Laboratories. 2004. Abbott Park IL. Adalimumab (Humira) package insert.
2. Breedveld FC, Weisman MH, Kavanaugh AF et al. 2006. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum, 54:26-37.
3. Burmester GR, Mariette X, Montecucco C, et al. 2007. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis, 66:732-9.
4. Calabrese LH. 2003. Molecular differences in anticytokine therapies. Clin Exp Rheumatol, 21:241-8
5. Chaudhari U, Romano P, Mulcahy LD, et al. 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet, 357:1842-7.
6. Den Broeder AA, van de Putte LBA, Rau R, et al. 2002. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol, 29:2288-98.
7. Furst DE, Schiff MH, Fleischmann RM, et al. 2003. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concominant standard anti-rheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol, 30:2563-71.
8. Gaylor ML, Duvic M. 2004. Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol, 3:77-9.
9. Gordon KB, Langley RG, Leonardi C, et al. 1998. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol, 38:478-85.
10. Gottlieb AB, Evans R, Li S, et al. 2004. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol, 51:534-42.
11. Gottlieb AB. 2003. Infliximab for psoriasis. J Am Acad Dermatol, 49: S112-17.
12. Gottlieb AB, Matheson RT, Lowe N, et al. 2003. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol, 139:1627-32; discussion, 1632.
13. Heydendael VM, Spuls PI, Opmeer BC, et al. 2003. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med, 349:658-65.
14. Kent J, Pangan A, Szczerbak N, et al. 2006. Serious infections in patients with rheumatoid arthritis in adalimumab clinical trials [abstract]. 15th Congress of the European Academy of Dermatology and Venereology (EADV), Rhodes, P023.116.2006.
15. Kreuger G, Koo J, Lebwohl M, et al. 2001. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient membership survey. Arch Dermatol, 137:280-4.
16. Krueger J, Gottlieb A, Miller B, et al. 2000. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol, 115:333.
17. Leonardi CL, Powers JL, Matheson RT, et al. 2003. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med, 349:2014-22.
18. Mease PJ, Goffe BS, Metz J, et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet, 356:385-90.
19. Menter A, Tyring SK, Gordon K, et al. 2007. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Derm. In press.
20. Moreland LW, Schiff M, Cohen S, et al. 2002. Safety and efficacy of up to 5 years of etanercept (Enbrel) therapy in rheumatoid arthritis. Presented at the European League Against Rheumatism, 12-15 June, 2002.
21. Papp KA. 2006. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res, 298:7-15.
22. Perez J, Kupper H, Okun M. 2006. Outcomes of screening for latent Tb in worldwide adalimumab clinical trials [abstract]. 15th Congress of the European Academy of Dermatology and Venereology (EADV), Rhodes, P035.100. 10-1-2006.
23. Pitarch G, Sanchez-Carazo JL, Mahiques L, et al. January 2007. Treatment of Psoriasis with Adalimumab. Clin Exp Dermatol, 32:18-22.
24. Rau R. 2002. Adalimumab (a fully human anti-tumor necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis, 61(suppl 2):ii70-73.
25. Reich K, Nestle FO, Papp K, et al. 2005. EXPRESS study investigators (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet, 366:1367-74.
26. Roenigk HH Jr, Auerbach R, Maibach H, et al. 1998. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol, 38:478-85.
27. Saurat J, Stingl G, Dubertrel L, et al. 2006. CHAMPION Phase III Trial Results: Adalimumab Efficacy and Safety Compared with Methotrexate and Placebo in Patients with Moderate to Severe Psoriasis [abstract]. 15th Congress of the European Academy of Dermatology and Venereology (EADV), Rhodes, P035.165.2006.
28. Schiff MH, Burmester GR, Kent JD, et al. 2006. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis, 65:889-94.
29. Shikiar R, Willian MK, Okun MM, et al. 2006. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes, 4:71.
30. Winterfield LS, Menter A, Gordon K, et al. 2005. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis, 64(Suppl 2): ii87-90.